Nitrogen Containing Patents (Class 514/716)
  • Patent number: 10071208
    Abstract: The device allows the pain associated with the insertion of a needle of a syringe into the skin to be reduced. To do this, this device comprises a sleeve, which has a first rear portion to at least partially receive the syringe with the needle and a second front portion fitted with an end part, through which an opening passes for passage of the needle. A front face of the end part is intended to be applied with pressure against the skin of a person before insertion of the needle into the skin. This front face of the end part is arranged to receive an active substance for desensitizing the skin. The active substance can be applied to the skin at the instant the terminal part presses on the penetration site to desensitize the skin.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: September 11, 2018
    Inventor: Karim-Frederic Marti
  • Patent number: 8945603
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 3, 2015
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Patent number: 8927579
    Abstract: A compound having formula I. R1, R2, R3 and R4 are independently H or lower alkyl. R5 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, arylamino, heteroarylamino, cycloalkylamino, heterocycloalkyl amino, arylthio, heteroarylthio, cycloalkylthio, heterocycloalkylthio, or cyclic olefin, any of which may be substituted or non-substituted; or substituted alkyl, substituted alkyl oxy or substituted alkyl amino wherein the substituent is an aryl, a heteroaryl, a cycloalkyl, a heterocycloalkyl or a cyclic olefin, any of which may be substituted or non-substituted. X is C or N. n and p are independently whole numbers selected from 0, 1 and 2. (CH2)n and (CH2)p may be substituted or non-substituted. Ar1 and Ar2 are independently aryl or heteroaryl groups which may be substituted or non-substituted. Certain specific compounds are excluded.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: January 6, 2015
    Inventors: Nnae-Meka Ikechukwu Amobi, Christopher Smith
  • Publication number: 20150004110
    Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 1, 2015
    Applicant: DIVERCHIM
    Inventors: Natacha Frison, Benoit Folleas, Jean-Louis Brayer, Florence Wafflart
  • Publication number: 20140329867
    Abstract: The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 6, 2014
    Applicant: Ecole Polytechnique Federale de Lausanne
    Inventors: Freddy Radtke, Rajwinder Lehal, Viktoria Reinmuller, Jieping Zhu
  • Patent number: 8808743
    Abstract: Benzonatate resinates of weak acid ion exchange resins having the same distribution of butyl 4-aminobenzoate homologs as exist in the benzonatate listed in the F.D.A. Orange Book as Application No. N011210. These resinates, in simulated gastrointestinal dissolution, release essentially the same distribution of butyl-4 aminobenzoate homologs as exist in the benzonatate listed in the F.D.A. Orange Book as Application No. N011210.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: August 19, 2014
    Inventors: William Wayne Howard, Russell Francis Somma
  • Patent number: 8778968
    Abstract: A compound having formula I. R1, R2, R3 and R4 are independently H or lower alkyl. R5 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, arylamino, heteroarylamino, cycloalkylamino, heterocycloalkyl amino, arylthio, heteroarylthio, cycloalkylthio, heterocycloalkylthio, or cyclic olefin, any of which may be substituted or non-substituted; or substituted alkyl, substituted alkyl oxy or substituted alkyl amino wherein the substituent is an aryl, a heteroaryl, a cycloalkyl, a heterocycloalkyl or a cyclic olefin, any of which may be substituted or non-substituted. X is C or N. n and p are independently whole numbers selected from 0, 1 and 2. (CH2)n and (CH2)p may be substituted or non-substituted. Ar1 and Ar2 are independently aryl or heteroaryl groups which may be substituted or non-substituted. Certain specific compounds are excluded.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: July 15, 2014
    Inventors: Nnaemeka Ikechukwu Amobi, Ian Christopher Smith
  • Publication number: 20140178374
    Abstract: The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Application
    Filed: August 17, 2012
    Publication date: June 26, 2014
    Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, EMORY UNIVERSITY
    Inventors: Xingming Deng, Jia Zhou, Chunyong Ding
  • Patent number: 8673340
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: March 18, 2014
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Patent number: 8641816
    Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Matthias S. Ober, Edward D. Daugs, Wanglin Yu, Cynthia L. Rand
  • Publication number: 20130274283
    Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Richard A. GATTI, Liutao DU, Robert DAMOISEAUX, Chih-Hung LAI, Michael JUNG, Jin-Mo KU, Carmen BERTONI
  • Patent number: 8558061
    Abstract: Methods to generate doubled haploid plants and plant components using low mammalian toxicity chromosome doubling agents are disclosed. Chromosome doubling agents provide low mortality rates and higher chromosome doubling rate in plants.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 15, 2013
    Assignee: Agrigenetics, Inc.
    Inventors: Yunxing Cory Cui, Paul R. Schmitzer, David H. Young
  • Patent number: 8497293
    Abstract: The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I): and the salts and N-oxides thereof.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 30, 2013
    Assignee: Syngenta Crop Protection LLC
    Inventors: Christoph Luethy, Anthony Cornelius O'Sullivan, Thomas Pitterna, Jurgen Harry Schaetzer
  • Patent number: 8415393
    Abstract: The present invention provides methods for the design and identification of novel antimicrobial compounds, and provides antimicrobial compounds identified using these methods. These antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide that binds to the prokaryotic single-stranded DNA binding protein. In some examples, the prokaryotic single-stranded DNA binding protein is prokaryotic Exonuclease I. In one embodiment, the antimicrobial compound has the structure wherein Y is selected from the group consisting of CH2, O, and NH, R1 is selected from the group consisting of H, F, Cl, Br, and I, R2 is selected from the group consisting of H and CF3, R3 is selected from the group consisting of H and CO2H, R4 is selected from the group consisting of H and OH, and R5 is selected from the group consisting of H, alkoxy, and NO2.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: April 9, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James L. Keck, Douglas A. Bernstein
  • Publication number: 20130053418
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Patent number: 8357398
    Abstract: Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 22, 2013
    Assignee: Alitair Pharmaceuticals Inc.
    Inventors: William Wayne Howard, Russell Francis Somma, Doreen Marie Frank
  • Patent number: 8318816
    Abstract: Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes (at physiologic pH, but can become active toward cell membranes if the environment is acidified below ca. pH 6.8), coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 27, 2012
    Assignee: University of Washington
    Inventors: Allan S. Hoffman, Patrick S. Stayton, Niren Murthy
  • Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Applicants: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS, ALLIANT TECHSYSTEMS INC.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20120178704
    Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.
    Type: Application
    Filed: December 7, 2007
    Publication date: July 12, 2012
    Inventors: Agnes M. Rimando, Nanjoo Suh, Cassia Mizuno, Bandaru s. Reddy, Sada L. Reddy
  • Patent number: 8192743
    Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: June 5, 2012
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventors: Hong Zhao, Richard B. Greenwald, Susan L. Adler, legal representative
  • Publication number: 20110294667
    Abstract: Suggested are agrochemical compositions, comprising (a) biocides, and (b) alkoxylation products of di- and/or oligosaccharide esters.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 1, 2011
    Inventors: Hans-Georg Mainx, Peter Hofer
  • Publication number: 20110230532
    Abstract: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Application
    Filed: July 27, 2009
    Publication date: September 22, 2011
    Inventors: Amjad Ali, Robert K. Baker, Kathleen M. Rupprecht, Michael Man-Chu Lo, Brent Whitehead
  • Patent number: 8012488
    Abstract: A novel polyoxyalkylene derivative represented by the following formula (1), wherein each symbol is as defined in the specification, which has a functional group capable of reacting with various physiologically active substances according to the object is provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: September 6, 2011
    Assignee: NOF Corporation
    Inventors: Kenji Sakanoue, Kenichiro Nakamoto, Yuji Yamamoto, Hiroki Yoshioka
  • Publication number: 20110130289
    Abstract: Agrochemical compositions comprising (a) one or more branched alkyl polyglycosides, and (b) one or more biocides are disclosed. The compositions display improved solubility in water, and reduced foam generation.
    Type: Application
    Filed: November 29, 2010
    Publication date: June 2, 2011
    Applicant: COGNIS IP MANAGEMENT GMBH
    Inventors: Barbara Stefl, Jianhua Mao
  • Publication number: 20110105507
    Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.
    Type: Application
    Filed: October 21, 2010
    Publication date: May 5, 2011
    Inventors: Matthias S. Ober, Edward D. Daugs, Wanglin Yu, Cynthia L. Rand
  • Publication number: 20110098331
    Abstract: The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, mollus and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I): and the salts and N-oxides thereof.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 28, 2011
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: Christoph Luethy, Anthony Cornelius O'Sullivan, Thomas Pitterna, Jurgen Harry Schaetzer
  • Publication number: 20110091552
    Abstract: The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.
    Type: Application
    Filed: December 27, 2010
    Publication date: April 21, 2011
    Inventors: Tim McCaffrey, Dmitry Gagarin, Zhaoqing Yang
  • Patent number: 7897698
    Abstract: The present application discloses a method of modifying a macromolecule, the method comprising the steps of (i) providing the macromolecule; (ii) providing a compound of the general formula (I): wherein N is a primary amino group protected with the protecting group P, wherein the protecting group involves both free valences of the primary amino group; m is an integer of 1-12 and n is an integer of 1-2000; R1 and R2 are independently selected from the group consisting of hydrogen and C1-4-alkyl; and X is a reactive group; and (iii) allowing the compound of the general formula (I) to react with the macromolecule so as to form grafts on the macromolecule. Compounds of the general formula (i) and a method for the preparation thereof are also disclosed.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: March 1, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Ib Johannsen, Roice Michael
  • Publication number: 20100317520
    Abstract: A control method against noxious organisms in a field of soybean or corn, which comprises applying one or more PPO-inhibiting compounds selected from the group consisting of flumioxazin, sulfentrazone, saflufenacil, oxyfluorfen and 3-(4-chloro-6-fluoro-2-trifluoromethylbenzimidazol-7-yl)-1-methyl-6-trifluoromethyl-2,4-(1H,3H)pyrimidinedione to soil or weeds in the field where soybean or corn seeds have been sown or where said seeds are to be sown, said seeds being treated with one or more compounds selected from the group consisting of neonicotinoid compounds, azole compounds, strobilurin compounds and metalaxyl compounds.
    Type: Application
    Filed: April 26, 2010
    Publication date: December 16, 2010
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Hajime IKEDA, Atsushi IWATA
  • Patent number: 7749526
    Abstract: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and X and Y, independently of one another, are a straightchain or branched alkylene bridge with 1 to 20 carbon atoms, preferably an alkylene bridge with 1 to 3 carbon atoms, which is unsubstituted or substituted by halogen, cyano or nitro. Furthermore, an essentially non-therapeutical process for deterring vermin is described, which is based on the usage of these compounds, as well as verminrepellent compositions containing these compounds as the active ingredient, and finally the use of these compounds for producing vermin-deterring compositions and their usage in deterring vermin from animals, humans and objects. New compounds within the scope of formula (I) are also described.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: July 6, 2010
    Assignee: Novartis AG
    Inventors: Thomas Goebel, Tania Cavaliero, Jacques Bouvier
  • Patent number: 7582803
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: September 1, 2009
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Sean Brown, Jonathan B. Houze, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Wei Qiu, Michael J. Schmitt, Yingcai Wang, Liusheng Zhu, Rajiv Sharma
  • Patent number: 7560491
    Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: July 14, 2009
    Assignees: Taipei Medical University, National Health Research Institutes
    Inventors: Jing-Ping Liou, Jang-Yang Chang
  • Patent number: 7420003
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: September 2, 2008
    Assignee: Astrazeneca AB
    Inventors: Keith Fagnou, Mark Lautens
  • Patent number: 7413738
    Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: August 19, 2008
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventors: Hong Zhao, Susan Adler, legal representative, Richard B. Greenwald
  • Publication number: 20080176955
    Abstract: Pharmaceutical compositions are provided containing a combination of benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof. Methods of using compositions comprising benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof, provide relief from cough, pulmonary congestion or both. The compositions and methods provide relief to opiate-sensitive individuals, in particular, as well as to infants and other pediatric patients.
    Type: Application
    Filed: January 16, 2008
    Publication date: July 24, 2008
    Applicant: VICTORY PHARMA, INC.
    Inventors: Thomas Heck, Michael Cvijanovich
  • Publication number: 20080096973
    Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.
    Type: Application
    Filed: January 19, 2007
    Publication date: April 24, 2008
    Applicants: Taipei Medical University, National Health Research Institutes
    Inventors: Jing-Ping Liou, Jang-Yang Chang
  • Publication number: 20080020981
    Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Inventor: Zachary Kevin Sweeney
  • Patent number: 7307071
    Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: December 11, 2007
    Assignee: Onyx Pharmaceuticals, Inc
    Inventors: John F. Lyons, Gideon Bollag
  • Patent number: 7276631
    Abstract: The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: October 2, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong-Jin Wu, Huan He
  • Patent number: 7250157
    Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: July 31, 2007
    Assignee: Applied Genetics Incorporated Dermatics
    Inventors: David A. Brown, Alexander A. Khorlin, Krystyna Lesiak, Wu Yun Ren
  • Patent number: 7135600
    Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: November 14, 2006
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Diane Mary Coe, Stephen Barry Guntrip, Brian Edgar Looker, Panayiotis Alexandrou Procopiou
  • Patent number: 7122189
    Abstract: Activated polymeric bicine derivatives such as as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: October 17, 2006
    Assignee: Enzon, Inc.
    Inventors: Hong Zhao, Richard B. Greenwald, Annapurna Pendri
  • Patent number: 7090831
    Abstract: The present invention relates to novel pharmaceutical aerosol formulations comprising: (A) salmeterol xinafoate in the form of particles coated by spray-drying with at least one surfactant in the absence of any other coating excipient, in suspension in (B) a liquefied propellant gas which is 1,1,1,2,3,3,3-heptafluoro-n-propane or 1,1,1,2-tetrafluoroethane and mixtures thereof for administration particularly by the pulmonary route and to a process for preparing these formulations. It also relates to novel particles suitable for use in such formulations.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: August 15, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Cecile Isabelle Bonvoisin, Christophe Laroche
  • Patent number: 7087229
    Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: August 8, 2006
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventors: Hong Zhao, Richard B. Greenwald
  • Patent number: 7048925
    Abstract: Polyacetals comprising a recurring units represented by a formula selected from the group consisting of formula (I) and (II): wherein A comprises at least one acetal group; B is selected from the group consisting of —CH—, —CH(CH3)—, CH2CH—, —CH2C(CH3)—, —CH(CH3)CH—, and —CHCH(CH3)CH(CH3)—; Z is selected from the group consisting of C(O)OR1, C(O)SR1, C(O)NR1R2, and VU; V is a linker group; U is selected from the group consisting of poly(ethyleneimine), poly(propyleneimine), poly(lysine), PAMAM dendrimer, octaamine dendrimer, hexadecaamine dendrimer, enhancer, and targeting receptor; R1 and R2 are each individually selected from the group consisting of hydrogen, C1 to C10 alkyl, and C6 to C10 aryl; D is a linkage selected from the group consisting of carboxylic amide, carboxylic ester, urea, and urethane; and G is selected from the group consisting of C4 to C20 alkyl, C6-C10 aryl, and —(OCH2CH2)n—, where n is in the range of 1 to about 250, are useful in nucleic acid delivery applications.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: May 23, 2006
    Assignee: Nitto Denko Corporation
    Inventors: Sang Van, Nitnara Viroonchatapan, Shouping Ji, Lei Yu
  • Patent number: 7030162
    Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: April 18, 2006
    Assignee: POZEN Inc.
    Inventors: John R. Plachetka, Zakauddin T. Chowhan
  • Patent number: 6955804
    Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: October 18, 2005
    Assignee: Applied Genetics Incorporated Dematics
    Inventors: David A. Brown, Alexander A. Khorlin, Krystyna Lesiak, Wu Yun Ren
  • Patent number: 6933321
    Abstract: Biphenyl derivatives are disclosed for use in the treatment of androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, precocious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness. For example, some preferred compounds having the structure: are formulated together with pharmaceutically acceptable diluent or carrier for topical use in the treatment of acne, hirutism, seborrhea or androgenic alopecia, or for systemic use in the treatment of androgen-dependent prostate cancer.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: August 23, 2005
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Shankar Mohan Singh, Van Luu-The
  • Patent number: 6933320
    Abstract: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are also provided.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: August 23, 2005
    Assignee: Aventis Pharma S. A.
    Inventor: Marie-Christine Bissery